- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07376577
Comparison of Postoperative Recovery Quality and Safety Between Anricofen Combined With Ciprofol and Sufentanil Combined With Ciprofol for Non-intubated Anesthesia During ERCP (Anricofen Cipr)
Comparison of Postoperative Recovery Quality and Safety Between Anricofen Combined With Ciprofol and Sufentanil Combined With Ciprofol for Non-intubated Anesthesia During Endoscopic Retrograde Cholangiopancreatography: A Randomized Controlled Trial
This study aims to compare postoperative recovery quality and safety between anricofen combined with ciprofol and sufentanil combined with ciprofol in patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) under non-intubated anesthesia.
This is a single-center, prospective, randomized, controlled study involving patients aged 18-80 years who are scheduled for elective ERCP. A total of 180 participants are planned to be enrolled and randomly assigned in a 1:1 ratio to two groups.
Participants in the anricofen group will receive intravenous anricofen (HSK21542) at a dose of 1 μg/kg before ciprofol induction. Participants in the sufentanil group will receive intravenous sufentanil at a dose of 0.1 μg/kg before ciprofol induction. Both groups will receive ciprofol for anesthesia induction and maintenance.
The primary outcome is the total Quality of Recovery-15 (QoR-15) score at 24 hours after the procedure. Secondary outcomes include postoperative pain scores at different time points, total ciprofol consumption, recovery time, post-anesthesia care unit stay, respiratory and hemodynamic adverse events, postoperative nausea and vomiting, and serious adverse events.
The study is expected to provide clinical evidence on the postoperative recovery quality and safety of these two analgesic regimens for patients undergoing ERCP under non-intubated anesthesia.
Обзор исследования
Статус
Вмешательство/лечение
Тип исследования
Регистрация (Оцененный)
Фаза
- Непригодный
Контакты и местонахождение
Контакты исследования
- Имя: Longhua Guo
- Номер телефона: 18303733012
- Электронная почта: 1535732839@qq.com
Места учебы
-
-
Henan
-
Xinxiang, Henan, Китай
- Рекрутинг
- The First Affiliated Hospital of Henan Medical University
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
**Inclusion Criteria:**
- Aged 18 to 80 years;
- American Society of Anesthesiologists (ASA) physical status I to III;
- Patients scheduled to undergo elective endoscopic retrograde cholangiopancreatography (ERCP).
**Exclusion Criteria:**
- Pregnancy or lactation;
- Obstructive sleep apnea (OSA);
- Long-term use of analgesics or psychotropic drugs, or a history of drug abuse;
- Coagulation dysfunction, bleeding tendency, or current anticoagulant therapy;
- Allergy to any of the study drugs;
- Severe cardiac, hepatic, renal, or other major organ diseases;
- Mental or cognitive impairment that prevents cooperation with the assessment;
- Inability to comply with the study protocol or complete follow-up;
- Requirement for tracheal intubation, postoperative transfer to the intensive care unit (ICU), or postoperative pancreatitis.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Двойной
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Anricofen(HSK21542) 1 μg/kg + Ciprofol
|
Anricofen (HSK21542) is a peripherally restricted κ-opioid receptor agonist. In this study, it is administered intravenously at a dose of 1 μg/kg 3 minutes before ciprofol induction by slow injection. Ciprofol is an intravenous sedative agent used for anesthesia induction and maintenance in this study. It is administered intravenously at an induction dose of 0.3 mg/kg by slow injection over more than 30 seconds. After the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score reaches 3 or below, ERCP is initiated. Anesthesia is maintained with a continuous infusion of ciprofol at 1.0-2.0 mg/kg/h. If patient movement or eye opening occurs during the procedure, an additional bolus of 0.10-0.15 mg/kg may be administered, with an interval of at least 2 minutes between additional doses. |
|
Активный компаратор: Sufentanil 0.1 μg/kg + Ciprofol
|
Ciprofol is an intravenous sedative agent used for anesthesia induction and maintenance in this study. It is administered intravenously at an induction dose of 0.3 mg/kg by slow injection over more than 30 seconds. After the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score reaches 3 or below, ERCP is initiated. Anesthesia is maintained with a continuous infusion of ciprofol at 1.0-2.0 mg/kg/h. If patient movement or eye opening occurs during the procedure, an additional bolus of 0.10-0.15 mg/kg may be administered, with an interval of at least 2 minutes between additional doses. Sufentanil is an opioid analgesic. In this study, it is used as the active comparator and administered intravenously at a dose of 0.1 μg/kg 3 minutes before ciprofol induction by slow injection. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Quality of Recovery-15 (QoR-15) Score at 24 Hours Postoperatively
Временное ограничение: 24 hours after the procedure
|
The primary outcome is the total score of the Quality of Recovery-15 (QoR-15) questionnaire at 24 hours after ERCP. The QoR-15 is a patient-reported measure of postoperative recovery quality, with total scores ranging from 0 to 150. Higher scores indicate better postoperative recovery quality. |
24 hours after the procedure
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Resting Numerical Rating Scale (NRS) Pain Score
Временное ограничение: At prespecified time points postoperatively
|
Resting pain intensity will be assessed using the Numerical Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain), at the prespecified postoperative assessment time points. |
At prespecified time points postoperatively
|
|
Total Ciprofol Consumption
Временное ограничение: During the ERCP procedure
|
The total dose of ciprofol administered to each participant during the ERCP procedure will be recorded and compared between the two groups. |
During the ERCP procedure
|
|
Respiratory and Hemodynamic Adverse Events
Временное ограничение: During the procedure and up to 24 hours postoperatively
|
The incidence and details of perioperative respiratory and hemodynamic adverse events will be recorded. Respiratory events include hypoxemia, apnea or significant hypoventilation, airway interventions, mask-assisted ventilation, supraglottic airway placement, and emergency tracheal intubation. Hemodynamic events include hypotension, bradycardia, and the use of vasoactive drugs such as norepinephrine or atropine. |
During the procedure and up to 24 hours postoperatively
|
|
Postoperative Nausea and Vomiting (PONV)
Временное ограничение: Within 24 hours postoperatively
|
The occurrence of postoperative nausea and vomiting will be recorded and compared between the two groups. |
Within 24 hours postoperatively
|
|
Serious Adverse Events (SAEs)
Временное ограничение: From enrollment until the end of the study
|
The occurrence, type, and details of serious adverse events will be recorded throughout the study period. |
From enrollment until the end of the study
|
|
Recovery Time
Временное ограничение: From the end of the ERCP procedure to recovery
|
The time required for participants to recover from anesthesia after the ERCP procedure will be recorded and compared between the two groups. |
From the end of the ERCP procedure to recovery
|
|
Post-Anesthesia Care Unit (PACU) Length of Stay
Временное ограничение: From PACU admission to PACU discharge
|
The duration of stay in the post-anesthesia care unit (PACU) after the procedure will be recorded and compared between the two groups. |
From PACU admission to PACU discharge
|
Соавторы и исследователи
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- XYFY-IIT-ANES-ERCP-2025-01
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .